Susquehanna Fundamental Investments LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,000 shares of the biopharmaceutical company’s stock, valued at approximately $209,000.
A number of other institutional investors have also added to or reduced their stakes in HALO. Rise Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $25,000. Whittier Trust Co. bought a new stake in Halozyme Therapeutics during the first quarter worth $27,000. GAMMA Investing LLC boosted its position in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics in the 2nd quarter valued at $33,000. Finally, Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $49,000. 97.79% of the stock is owned by institutional investors.
Insider Transactions at Halozyme Therapeutics
In related news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at approximately $834,836.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at approximately $40,063,244.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 84,881 shares of company stock valued at $4,932,284. 2.40% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on Halozyme Therapeutics
Halozyme Therapeutics Stock Down 2.1 %
Halozyme Therapeutics stock opened at $59.18 on Friday. The firm has a 50 day simple moving average of $58.96 and a 200 day simple moving average of $50.28. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. Halozyme Therapeutics, Inc. has a 1-year low of $32.83 and a 1-year high of $65.53. The firm has a market capitalization of $7.53 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 0.56 and a beta of 1.27.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.68 earnings per share. On average, analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Recommended Stories
- Five stocks we like better than Halozyme Therapeutics
- Election Stocks: How Elections Affect the Stock Market
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What Does a Stock Split Mean?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Why Are These Companies Considered Blue Chips?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.